secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-09-17T23:59:59+00:00
Accession:  0001999371-25-013413
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix in-licenses Phase 2/3-ready Lyme disease antibody TNX-4800
----------------------------------------------------------------

- In-licensed worldwide rights to TNX-4800, a fully human monoclonal antibody targeting OspA of Borrelia burgdorferi.
- Designed as a single subcutaneous dose each Spring to protect against Lyme disease through Fall tick season.
- Positive Phase 1 study showed safety, tolerability, and linear PK/PD/efficacy relationship (1:1:1).
- Planning adaptive Phase 2/3 study; ~70 million people in U.S. endemic areas eligible for treatment.
- Developed by UMass Chan Medical School; no FDA-approved vaccines currently available for Lyme disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125013413/0001999371-25-013413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125013413/tnxp-8k_091725.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-013413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer